Cushing's syndrome: Drug targets and therapeutic options

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 10, 2002, Pages 1537-1546

  Páez Pereda, Marcelo ^a   Arzt, Eduardo ^a   Stalla, Günter K ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adrenocorticotropic hormone (ACTH); Cushing's syndrome; Glucocorticoids; Hypothalamus pituitary adrenal (HPA) axis; Pro opiomelanocortin (POMC)

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID; ANTIRETROVIRUS AGENT; BROMOCRIPTINE; CABASAR; CABERGOLINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYPROHEPTADINE; DOPAMINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; EXTINA; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLUTETHIMIDE; KETOCONAZOLE; MEMBRANE RECEPTOR; METYRAPONE; MITOTANE; NORADRENALIN UPTAKE INHIBITOR; OCTREOTIDE; PROTEIN P27; PROTEIN P53; PROTEINASE INHIBITOR; QUINAGOLIDE; RETINOIC ACID; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; CANCER SURGERY; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CUSHING SYNDROME; DEPRESSION; DIABETES INSIPIDUS; DRUG TARGETING; ENDOCRINE DISEASE; ENERGY METABOLISM; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIPID STORAGE; LUNG TUMOR; METABOLIC DISORDER; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OBESITY; PROTEIN METABOLISM; REVIEW;

EID: 0036799285     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.10.1537     Document Type: Review

References (78)

1. ORTH DN: Cushing's syndrome. New Engl. J. Med. (1995) 332:791-803.
2. DAHIA PLM, GROSSMAN A: The molecular pathogenesis of corticotroph tumours. Endocr. Rev. (1999) 20:136-155.
3. WAJCHENBERG BL, MENDONCA BB, LIBERMAN B et al.: Ectopic adrenocorticotropic hormone syndrome. Endocr. Rev. (1994) 15:752-787.
4. BOSCARO M, BARZON L, FALLO F, SONINON: Cushing's syndrome. Lancet (2001) 357:783-791.
5. WAJCHENBERG BL, ALBERGARIA PEREIRA MA, MEDONCA BB et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer (2000) 88(4):711-736.
6. MILLER JW, CRAPO L: The medical treatment of Cushing's syndrome. Endocr. Rev. (1993) 14(4):443-458.
7. MALLON PW, COOPER DA, CARR A: HIV-associated lipodystrophy. HIV Med. (2001) 2:166-173.
8. GRINSPOON S: Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab. (2001) 12(9):413-419.
9. COLAO A, DI SARNO A, MARZULLO, P et al.: New medical approaches in pituitary adenomas. Horm. Res. (2000) 53:76-87.
10. ALEXANDER JM, BILLER BM, BIKKAL H, ZERVAS NT, ARNOLD A, KLIBANSKI A. Clinically non-functioning pituitary rumours are monoclonal in origin. J. Clin. Invest. (1990) 86:336-340.
11. CLAYTON RN, FARRELL WE: Clonality of pituitary rumours: more complicated than initially envisaged? Brain Pathol. (2001) 11(3):313-327.
12. RAY D, MELMED S: Pituitary cytokine and growth factor expression and action. Endocr. Rev. (1997) 18:206-228.
13. RENNER U, PAGOTTO U, ARZT E, STALLA GK: Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur. J. Endocrinol. (1996) 135:515-532.
14. ARZT E, PEREDA MP, CASTRO CP, PAGOTTO U, RENNER U, STALLA GK: Pathophysiological role of the cytokine network in the anterior pituitary gland. Front. Neuroendocrinol (1999) 20(1):71-95.
15. REUL JM, HOLSBOER F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. (2002) 2(1):23-33.
16. 3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumours. Horm. Res. (1997) 47(4-6):259-262.
17. BOUTILLIER AL, MONNIER D, LORANG D, LUNDBLAD JR, ROBERTS JL, LOEFLER JP: Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and-independent pathways: characterization of an AP-1 site in exon 1. Mol. Endocrinol. (1995) 9:745-755.
18. AUTELITANO DJ, COHEN DR: CRF stimulates expression of multiple fos and jun related genes in the AtT-20 corticotroph cell. Mol. Cell. Endocrinol. (1999) 119:25-35.
19. TIMPL P. SPANAGEL R, SILLABER I, et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat. Genet. (1998) 19(2):162-166.
20. DIETERICH KD, GUNDELFINGER ED, LUDECKE DK, LEHNERT H: Mutation and expression analysis of corticoctropin-releasing Factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. (1998) 83(9):3327-3331.
21. BOUSQUET C, SUSINI C, MELMED S: Inhibitory toles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J. Clin. Invest. (1999) 104(9):1277-1285.
22. BOUSQUET C, ZATELLI MC, MELMED S: Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immunoneuroendocrine interfacing. J. Clin. Invest. (2000) 106:1417-1425.
23. AUERNHAMMER CJ, MELMED S: Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr. Rev. (2000) 21(3):313-345.
24. ARZT E, STELZER G, RENNER U, LANGE M, MULLER OA, STALLA GK: Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. J. Clin. Invest. (1992) 90:1944-1951.
25. ARZT E, BURIC R, STELZER G et al.: Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology (1993) 132:459-467.
26. DE HERDER WW, HOFLAND LJ, USDIN TB et al.: Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J. Clin. Endocrinol. Metab. (1996) 81(9):3168-3172.
27. LACROIX A, N'DIAYE N, MIRCESCU H, TREMBLAY J, HAMET P: The diversity of abnormal hormone receptors in adrenal Cushing's syndrome allows novel pharmacological therapies. Braz. J. Med. Biol. Res. (2000) 33(10):1201-1209.
28. GROUSSIN L, PERLEMOINE K, CONTESSE V et al.: The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in actrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J. Clin. Endocrinol. Metab. (2002) 87(5):1980-1985.
29. ENGLER D, REDEI E, KOLA I: The cortcotropin-release inhibitory factor hypothesis: a review of the evidence for the existence of inhibitory as well as stimulatory hypophysiotropic regulation of adrenocorticotropin secretion and biosynthesis. Endocr. Rev. (1999) 20(4):460-500.
30. GIRALDI FP, CAVAGNINI F: Corticotropin-releasing hormone is produced by rat corticotropes and modulates ACTH secretion in a paracrine/autocrine fashion. J. Clin. Invest. (1998) 101(11):2478-2484.
31. CHILDS GV, ROUGEAU D, UNABIA G: Corticotropin-releasing hormone and epidermal growth factor: mitogens for anterior pituitary corticotropes. Endocrinology (1995) 136:1595-1602.
32. BRADBURY MJ, MCBURNIE MI, DENTON DA, LEE KF, VALE WW: Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology (2000) 141(8):2715-2724.
33. CULLEN MJ, LING N, FOSTER AC, PELLEYMOUNTER MA: Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology (2001) 142(3):992-999.
34. LUTON JP, MAHOUDEAU JA. BOUCHARD P et al.: Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N. Engl. J. Med. (1979) 300(9):459-464.
35. LUBITZ JA, FREEMAN L, OKUN R: Mitotane use in inoperable adrenal cortical carcinoma. JAMA (1973) 223(10):1109-1112.
36. CIZZA G, CHROUSOS GP: Adrenocorticotrophic hormone-dependent Cushing's syndrome. Cancer Treat. Res. (1997) 89:25-40.
37. CHU JW, MATTHIAS DF, BELANOFF J, SCHATZBERG A, HOFFMAN AR, FELDMAN D: Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. (2001) 86(8):3568-3573.
38. BERTAGNA X, BERTAGNA C, LAUDAT MH, HUSSON JM, GIRARD F, LUTON JP: Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J. Clin. Endocrinol. Metab. (1986) 63(3):639-643.
39. BERTAGNA X, BASIN C, PICARD F et al.: Peripheral antiglucocorticoid action of RU 486 in man. Clin. Endocrinol. (1988) 28(5):537-541.
40. WOLKOWITZ OM, REUS VI: Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. (1999) 61(5):698-711.
41. SONINO N, BOSCARO M, MEROLA G, MANTERO F: Prolonged treatment of Cushing's disease by ketoconazole. J. Clin. Endocrinol. Metab. (1985) 61(4):718-722.
42. STALLA GK, STALLA J, LOEFFLER JP, VON WERDER K, MULLER OA: Pharmacological modulation of CRH-stimulated ACTH secretion by ketoconazole. Horm. Metab. Res. Suppl. (1987) 16:31-36.
43. STALLA GK, STALLA J, HUBER M et al.: Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology (1988) 122(2):618-623.
44. STALLA GY, STALLA J, VON WERDER K et al.: Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology (1989) 125(2):699-706.
45. ERIKSSON B, OBERG K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumours: future outlook. Ann. Oncol. (1999) 10(Suppl 2):31-38.
46. LAMBERTS SW, KRENNING EP, REUBI JC: The role of somatostatin and its analogues in the diagnosis and treatment of tumours. Endocr. Rev. (1991) 12:450-482.
47. VON WERDER K, MULLER OA, STALLA GK: Somatostatin analogues in ectopic corticotropin production. Metabolism (1996) 45(8 Suppl 1):129-131.
48. DE HERDER WW, VAN DER LELY AJ, LAMBERTS SW: Somatostatin analogue treatment of neuroendocrine tumours. Postgr. Med. J. (1996) 72(849):403-408.
49. GREENMAN Y, MELMED S: Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumours. J. Clin. Endocrinol. Metab. (1994) 78:398-403.
50. HOFLAND LJ, VISSER-WISSELAAR. HA, LAMBERTS SW: Somatostatin analogues: clinical application in relation to human somatostatin receptor subtypes. Biochem. Pharmacol. (1995) 50:287-297.
51. MEZEY E, HUNYADY B, MITRAS et al.: Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology (1998) 139:414-419.
52. MERCADO-ASIS LB, YASUDA K, MURAYAMA M, MUNE T, MORITA H, MIURA K: Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol. Jpn. (1992) 39(4):385-395.
53. BERWAERTS J, VERHELST J, MAHLER C, ABS R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol. Endocrinol. (1999) 13(3):175-182.
54. ISHIBASHI M, YAMAJI T: Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. J. Clin. Invest. (1981) 68(4):1018-1027.
55. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 Mutations in human cancers. Science (1991) 253:49-53.
56. HARVEY M, VOGEL H, LEE EY, BRADLEY A, DONEHOWER. LA: Mice deficient in both p53 and Rb develop tumours primarily of endocrine origin. Cancer Res. (1995) 55:1146-1151.
57. JACKS T, FAZELI A, SCHMITT EM, BRONSON RT, GOODELL MA, WEINBERG RA: Effects of an Rb mutation in the mouse. Nature (1992) 359:295-300.
58. THAPAR K, SCHEITHAUER BW, KOVACS K, PERNICONE PJ, LAWS ER Jr: p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumour growth fractions. Neurosurgery (1996) 38:763-770.
59. BUCKLEY N, BATES AS, BROOME JC et al.: P53 protein accumulates in Cushings adenomas and invasive non-functional adenomas. J. Clin. Endocrinol. Metab. (1994) 79(5):1513-1516.
60. KONTOGEORGOS G, KAPRANOS N, THODOU E, SAMBAZIOTIS D, TSAGARAKIS S: Immunocytochemical accumulation of p53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis. Pituitary (1999) 1:207-212.
61. FERO ML, RIVKIN M, TASCH M et al.: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 85:733-744.
62. NAKAYAMA K, ISHIDA N, SHIRANE M et al.: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumours. Cell (1996) 85:707-720.
63. FERO ML, RANDEL E, GURLEY KE, ROBERTS JM, KEMP CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (1998) 396:177-180.
64. IKEDA H, YOSHIMOTO T, SHIDA N: Molecular analysis of p2l and p27 genes in human pituitary adenomas. Br. J. Cancer (1997) 76:1119-1123.
65. DAHIA PL, AGUIAR RC, HONEGGER J et al.: Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene (1998) 16:69-76.
66. TAKEUCHI S, KOEFFLER HP, HINTON DR, MIYOSHI L MELMED S, SHIMON I: Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumours. J. Endocrinol. (1998) 157:337-341.
67. BAMBERGER CM, FEHN M, BAMBERGER AM et al.: Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur. J. Endocrinol. (1999) 140:250-255.
68. LIDHAR K, KORBONITS M, JORDAN S et al.: Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumours, and malignant pituitary tumours. J. Clin. Endocrinol. Metab. (1999) 84:3823-3830.
69. SPENGLER D., VILLALBA M, HOFFMANN A et al.: Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J. (1997) 16:2814-2825.
70. PAGOTTO U, ARZBERGER T, CIANI E et al.: Inhibition of Zac1, a new gene diffiereritially expressed in the anterior pituitary, increases cell proliferation. Endocrinology (1999) 140:987-996.
71. THERRIEN M, DROUIN J: Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. Mol. Cell. Biol. (1991) 11:3492-3503.
72. PHILIPS A, LESAGE S, GINGRAS R et al.: Novel dimeric Nur77 signalling mechanism in endocrine and lymphoid cells. Mol. Cell. Biol. (1997) 17:5946-5951.
73. KOVALOVSKY D, REFOJO D, LIBERMAN AC et al: Activation and induction of nur77/nurr1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol. Endocrinol. (2002) 16(7):1638-1651.
74. PEREIRA FA, TSAI MJ, TSAI SY: COUP TF orphan nuclear receptors in development and differentiation. Cell Mol. Life Sci. (2000) 57:1388-1398.
75. PAEZ-PEREDA M, KOVALOVSKY D, HOPFNER U et al.: Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. (2001) 108:1123-1131.
76. WU Q, LI Y, LIU R et al.: Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J. (1997) 16:1656-1669.
77. KLIEWER SA, KAZUHIKO U, HEYMAN RA, MANGELSDORF DJ, DYCK JA, EVANS RM: Retinoid X receptor-COUP-TF interactions modulate retinoic acid signalling. Proc. Natl. Acad. Sci. USA (1992) 8;-1448-1452.
78. LOTAN R: Retinoids in cancer chemoprevention. FASEB J. (1996) 10:1031-1039.